TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fennec Pharmaceuticals ( (TSE:FRX) ) has issued an announcement.
On November 13, 2025, Fennec Pharmaceuticals announced an underwriting agreement to issue and sell 4,666,667 common shares at $7.50 per share, with a 30-day option for underwriters to purchase an additional 700,000 shares. The offering, expected to close on November 17, 2025, aims to raise funds for repurchasing and redeeming certain indebtedness and for general corporate purposes, potentially impacting the company’s financial stability and market operations.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on TSE:FRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.
Fennec Pharmaceuticals shows strong revenue growth and improved cash flow, key for its industry. However, profitability issues and a weak balance sheet weigh down the score. Technical indicators and valuation reflect mixed signals, while positive earnings call sentiments provide some optimism. Addressing financial challenges will be crucial for future performance.
To see Spark’s full report on TSE:FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company dedicated to combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy. The company focuses on the commercialization of PEDMARK® to mitigate the risk of platinum-induced ototoxicity, with FDA approval in the U.S. and European Commission approval under the brand name PEDMARQSI® in Europe and the U.K. Fennec has secured an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for commercialization in Europe, U.K., Australia, and New Zealand, and holds patents protecting PEDMARK® until 2039.
YTD Price Performance: 22.93%
Average Trading Volume: 1,369
Technical Sentiment Signal: Buy
Current Market Cap: C$313.5M
See more data about FRX stock on TipRanks’ Stock Analysis page.